HUMACYTE INC. - COMMO

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

22 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

21 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Third Quarter 2024 Financial Results and Business Update

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

28 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

08 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

04 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

26 Sep 2024 16:26:25 By Nasdaq GlobeNewswire

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

19 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte to Participate at Upcoming Investor Conferences in September

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

27 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Second Quarter 2024 Financial Results and Business Update

13 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

09 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

31 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire